1. Scrip
  2. >>Business
  3. >>Strategy

Iovance Biotherapeutics CEO On TIL Immunotherapy For Solid Tumors

 
• By Sten Stovall

2018 will be a big year for the clinical stage biotechnology company, which is banking on progressing novel tumor infiltrating lymphocytes for the treatment of solid tumors.

Laboratory
Iovance Is Developing Transformative Tumor-Infiltrating Lymphocyte (TIL) Therapies • Source: Shutterstock

Iovance Biotherapeutics Inc. CEO Maria Fardis says 2018 will be a key year in mapping the regulatory and commercialization path for both of its lead investigative adoptive cell therapies which use personalized tumor-infiltrating lymphocyte (TIL) technology to treat solid tumors.

While CAR-T technology has been getting much attention recently in the immuno-oncology space, Iovance is working on another type of immunotherapy by developing TILs and using the body's immune system to treat patients with aggressive

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.